GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CRISPR Therapeutics AG (STU:1CG) » Definitions » Price-to-Funds-From-Operations

CRISPR Therapeutics AG (STU:1CG) Price-to-Funds-From-Operations : (As of May. 31, 2024)


View and export this data going back to 2016. Start your Free Trial

What is CRISPR Therapeutics AG Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.


CRISPR Therapeutics AG (STU:1CG) Business Description

Traded in Other Exchanges
Address
Baarerstrasse 14, Zug, CHE, CH-6300
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, exa-cel, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.